1,680 reports of this reaction
1.9% of all FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE reports
#10 most reported adverse reaction
FATIGUE is the #10 most commonly reported adverse reaction for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, manufactured by GlaxoSmithKline LLC. There are 1,680 FDA adverse event reports linking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE to FATIGUE. This represents approximately 1.9% of all 88,399 adverse event reports for this drug.
Patients taking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 1,680 FDA reports for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 1.9% of all adverse event reports for FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, making it a notable side effect.
If you experience fatigue while taking FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.